|1.||Fedorova, Olga V: 4 articles (12/2012 - 12/2008)|
|2.||Bagrov, Alexei Y: 4 articles (12/2012 - 12/2008)|
|3.||Adair, C David: 3 articles (12/2012 - 09/2010)|
|4.||Frolova, Elena V: 3 articles (12/2012 - 12/2008)|
|5.||Adair, C D: 3 articles (04/2009 - 02/2009)|
|6.||Bzhelyansky, Anton M: 2 articles (12/2012 - 02/2010)|
|7.||Graves, Steven W: 2 articles (02/2011 - 09/2010)|
|8.||Danoff, Theodore M: 2 articles (09/2010 - 07/2008)|
|9.||Nikitina, Elena R: 2 articles (02/2010 - 12/2008)|
|10.||Tapilskaya, Natalia I: 2 articles (02/2010 - 12/2008)|
04/15/1996 - "[Digoxin poisoning treated with Digibind]."
06/01/1990 - "We report the use of digoxin immune Fab in a seven-day-old male neonate for treatment of digoxin poisoning. "
11/01/1987 - "Fatal digoxin poisoning: an unsuccessful resuscitation with use of digoxin-immune Fab."
06/01/2000 - "Intravenous administration of digoxin-specific antibody Fab fragments (Digidot) was effective, with a rapid improvement of the digitalis poisoning. "
07/01/2004 - "Digoxin-specific Fab (Digibind) is a mixture of antidigoxin Fab fragments prepared from sheep sera and is used as a treatment for digoxin poisoning. "
|2.||Hypertension (High Blood Pressure)
09/01/2000 - "Further, blocking the action of OLC with digibind or a novel anti-ouabain agent has been observed to lower blood pressure in several models of experimental and clinical hypertension. "
06/01/1995 - "These results indicate that chronic intracerebroventricular infusion of Digibind augmented reduced renal mass-saline hypertension in rats and suggest that brain ouabain-like compound may play a protective role against the elevation of blood pressure, at least in this model of hypertension."
06/01/1999 - "To further clarify the role of EDLF on the development of hypertension and renal water-sodium handling in 5/6 reduced renal mass hypertensive rats (RRM), we studied the effects of acute administration of digoxin-specific antibody Fab fragment (Digibind) in the early phase and the chronic phase of hypertension in RRM. "
03/01/1998 - "Furthermore, blocking the action of ouabain-like factor with digibind or a novel anti-ouabain agent lowers blood pressure in several models of hypertension. "
03/01/1997 - "Hemodynamic effects of the Fab fragment of digoxin antibody (digibind) in corticotropin (ACTH)-induced hypertension."
09/01/2010 - "We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. "
09/01/2010 - "Digoxin immune fab treatment for severe preeclampsia."
04/01/2010 - "The treatment of preeclampsia in a rat model employing Digibind."
04/01/2009 - "This hypothesis is supported by two cases of preeclampsia in which administration of digoxin immune Fab (DIF) reduced mean arterial pressure (MAP). "
12/01/2008 - "As compared with 3E9 mAb, Digibind, an affinity-purified antidigoxin antibody, was less active with respect to lowering BP in both hypertensive models and to restoration of NKA from erythrocytes from patients with preeclampsia. "
|4.||Renal Insufficiency (Renal Failure)
10/01/1993 - "Disposition of digoxin immune Fab in patients with kidney failure."
11/01/1991 - "Possible dissociation of the Digibind-digoxin complex in renal failure."
10/01/1994 - "Acute digoxin overdose in a newborn with renal failure: use of digoxin immune Fab and peritoneal dialysis."
06/01/1989 - "Free and total serum digoxin concentrations in a renal failure patient after treatment with digoxin immune Fab."
|5.||Cardiomegaly (Heart Hypertrophy)
01/01/2011 - "In separate experiments, chronic Digibind treatment prevented the rapid progression of cardiac hypertrophy and fibrosis in α1(S/S)α2(R/R) mice. "
06/01/2012 - "In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery. "
|2.||Immunoglobulin Fab Fragments
|4.||Immunoglobulin G (IgG)
|5.||Adrenocorticotropic Hormone (ACTH)
|6.||salicylhydroxamic acid (SHAM)
|7.||Ouabain (G Strophanthin)
|9.||Adenosine Triphosphatases (ATPase)
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Extracorporeal Membrane Oxygenation (ECMO)